Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant cardiac tumors].

Philippe Debourdeau1, Joseph Gligorov, Luis Teixeira

  • 1Service de Médecine Interne, Hôpital Desgenettes, 108, boulevard Pinel, 69003 Lyon. philippe.debourdeau@9oneline.fr

Bulletin Du Cancer
|May 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Breast (Edinburgh, Scotland)·2026
Same author

API-CAT Investigators' Decisions on Anticoagulation following Extended Treatment for Cancer VTE.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Functional Estrogen Receptor Assessment: Insights From Discordant 18F-FES PET/CT and ER Immunohistochemistry.

Clinical nuclear medicine·2026
Same author

Social disparities in the frequency and severity of triple-negative breast cancer at diagnosis in a university hospital in Paris, France: confronting race and ethnic blindness.

PloS one·2026
Same author

Impact of Neoadjuvant Chemotherapy Administration Time of Day on Pathological Response in Patients with Early Triple-Negative Breast Cancer.

Cancers·2026
Same author

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

The New England journal of medicine·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
Same journal

[Robotics in oncological surgery].

Bulletin du cancer·2026
See all related articles

Cardiac neoplasms are rare, often secondary to widespread cancer. Diagnosis is aided by imaging, but prognosis is poor, with treatment focusing on supportive care or careful surgical consideration.

Area of Science:

  • Cardiovascular pathology
  • Oncology

Context:

  • Cardiac neoplasms are rare, comprising <1% of cardiac surgeries and 0.1% of echocardiographic studies.
  • Secondary cardiac tumors, often from lung, breast, or pancreas cancers, indicate widespread metastasis.

Purpose:

  • To review the incidence, presentation, diagnosis, and management of primary and secondary cardiac neoplasms.
  • To highlight the diagnostic utility of cardiac echography and MRI.
  • To discuss treatment challenges and prognosis.

Summary:

  • Primary cardiac tumors are typically high-grade sarcomas with high metastatic potential.
  • Symptoms are often nonspecific, late-onset, or absent in secondary cardiac tumors.
  • Diagnosis relies on imaging (echocardiography, MRI), with poor prognosis dictating management.

Related Experiment Videos

Impact:

  • Emphasizes the limited treatment options for cardiac metastases, primarily supportive care.
  • Suggests cautious consideration of surgery for primary cardiac tumors due to high risk of rapid metastasis.
  • Underscores the importance of early diagnosis for potentially improving outcomes in rare cardiac malignancies.